News
-
July 8, 2011
Seaside Therapeutics Presents Phase 2 Data Autism Spectrum Disorders at the 42nd Autism Society National Conference -
June 21, 2011
Seaside Therapeutics Initiates Phase 2b Study of STX209 in Autism Spectrum Disorders -
June 2, 2011
Seaside Therapeutics Initiates Pivotal Phase 3 Study of STX209 in Fragile X Syndrome -
May 18, 2011
Seaside Therapeutics Publishes Review of Advances in the Treatment of Fragile X Syndrome in American Chemical Society Chemical Neuroscience -
September 9, 2010
Seaside Therapeutics Reports Positive Data from Phase 2 Study of STX209 in Autism Spectrum Disorders -
July 26, 2010
Seaside Therapeutics Reports Data from Randomized, Placebo-Controlled Phase 2 Study in Fragile X Syndrome -
July 20, 2010
Seaside Therapeutics Appoints Leading Industry Executives to its Board of Directors